APO RESEARCH · REPORT
5 Nucleotidase
5 Nucleotidase refers to research coverage of agents targeting 5-prime nucleotidase/CD73 within the selected edition.
Product & engineering
Understand the product.
The selected edition names investigational agents rather than bulk enzyme supply. Target identity, agent, development stage and study scope are distinct; inclusion is not evidence of approval or treatment efficacy.
What turns activity into demand
Distinguish equipment procurement, recurring materials and any related service within the selected study. Research use, educational use and clinical use have different acceptance requirements and should not be treated as one demand measure.
The commercial boundary
Separate research materials, devices and services within the selected edition. Approvals, labelled use and clinical acceptance need their own evidence; no medical suitability follows from this illustration.
Which supplied scope and interfaces define 5 Nucleotidase?
The selected edition names investigational agents rather than bulk enzyme supply. Target identity, agent, development stage and study scope are distinct; inclusion is not evidence of approval or treatment efficacy.
Technical reading
Selected research
Market Structure
Global 5 Nucleotidase Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global 5 Nucleotidase market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for 5 Nucleotidase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for 5 Nucleotidase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for 5 Nucleotidase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for 5 Nucleotidase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of 5 Nucleotidase include Bristol-Myers Squibb Co, Corvus Pharmaceuticals Inc, Innate Pharma SA, MedImmune LLC and Surface Oncology Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global 5 Nucleotidase market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of 5 Nucleotidase and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents 5 Nucleotidase sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the 5 Nucleotidase market size, projected growth trends, production technologies, key applications, and end-use industries.
5 Nucleotidase Segment by Company
Bristol-Myers Squibb Co
Corvus Pharmaceuticals Inc
Innate Pharma SA
MedImmune LLC
Surface Oncology Inc
5 Nucleotidase Segment by Type
IPH-53
CPX-006
BMS-986179
AB-680
Others
5 Nucleotidase Segment by Application
Colorectal Cancer
Fallopian Tube Cancer
Gastric Cancer
Metastatic Colorectal Cancer
Others
5 Nucleotidase Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global 5 Nucleotidase market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of 5 Nucleotidase and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of 5 Nucleotidase.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the 5 Nucleotidase market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of 5 Nucleotidase manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of 5 Nucleotidase in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of 5 Nucleotidase in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- IPH-53
- CPX-006
- BMS-986179
- AB-680
- Others
Applications
- Colorectal Cancer
- Fallopian Tube Cancer
- Gastric Cancer
- Metastatic Colorectal Cancer
- Others
Companies covered
- Bristol-Myers Squibb Co
- Corvus Pharmaceuticals Inc
- Innate Pharma SA
- MedImmune LLC
- Surface Oncology Inc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global 5 Nucleotidase Market Size, 2021 VS 2025 VS 2032
- 1.3 Global 5 Nucleotidase Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global 5 Nucleotidase Sales Estimates and Forecasts (2021-2032)
- 1.5 Global 5 Nucleotidase Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global 5 Nucleotidase Market Dynamics
- 2.1 5 Nucleotidase Industry Trends
- 2.2 5 Nucleotidase Industry Drivers
- 2.3 5 Nucleotidase Industry Opportunities and Challenges
- 2.4 5 Nucleotidase Industry Restraints
3 5 Nucleotidase Market by Manufacturers
- 3.1 Global 5 Nucleotidase Revenue by Manufacturers (2021-2026)
- 3.2 Global 5 Nucleotidase Sales by Manufacturers (2021-2026)
- 3.3 Global 5 Nucleotidase Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global 5 Nucleotidase Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global 5 Nucleotidase Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global 5 Nucleotidase Manufacturers, Product Type & Application
- 3.7 Global 5 Nucleotidase Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global 5 Nucleotidase Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 5 Nucleotidase Players Market Share by Revenue in 2025
- 3.8.3 2025 5 Nucleotidase Tier 1, Tier 2, and Tier 3
4 5 Nucleotidase Market by Type
- 4.1 5 Nucleotidase Type Introduction
- 4.1.1 IPH-53
- 4.1.2 CPX-006
- 4.1.3 BMS-986179
- 4.1.4 AB-680
- 4.1.5 Others
- 4.2 Global 5 Nucleotidase Sales by Type
- 4.2.1 Global 5 Nucleotidase Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global 5 Nucleotidase Sales by Type (2021-2032)
- 4.2.3 Global 5 Nucleotidase Sales Market Share by Type (2021-2032)
- 4.3 Global 5 Nucleotidase Revenue by Type
- 4.3.1 Global 5 Nucleotidase Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global 5 Nucleotidase Revenue by Type (2021-2032)
- 4.3.3 Global 5 Nucleotidase Revenue Market Share by Type (2021-2032)
5 5 Nucleotidase Market by Application
- 5.1 5 Nucleotidase Application Introduction
- 5.1.1 Colorectal Cancer
- 5.1.2 Fallopian Tube Cancer
- 5.1.3 Gastric Cancer
- 5.1.4 Metastatic Colorectal Cancer
- 5.1.5 Others
- 5.2 Global 5 Nucleotidase Sales by Application
- 5.2.1 Global 5 Nucleotidase Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global 5 Nucleotidase Sales by Application (2021-2032)
- 5.2.3 Global 5 Nucleotidase Sales Market Share by Application (2021-2032)
- 5.3 Global 5 Nucleotidase Revenue by Application
- 5.3.1 Global 5 Nucleotidase Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global 5 Nucleotidase Revenue by Application (2021-2032)
- 5.3.3 Global 5 Nucleotidase Revenue Market Share by Application (2021-2032)
6 Global 5 Nucleotidase Sales by Region
- 6.1 Global 5 Nucleotidase Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global 5 Nucleotidase Sales by Region (2021-2032)
- 6.2.1 Global 5 Nucleotidase Sales by Region (2021-2026)
- 6.2.2 Global 5 Nucleotidase Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America 5 Nucleotidase Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America 5 Nucleotidase Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe 5 Nucleotidase Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe 5 Nucleotidase Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific 5 Nucleotidase Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific 5 Nucleotidase Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa 5 Nucleotidase Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa 5 Nucleotidase Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global 5 Nucleotidase Revenue by Region
- 7.1 Global 5 Nucleotidase Revenue by Region
- 7.1.1 Global 5 Nucleotidase Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global 5 Nucleotidase Revenue by Region (2021-2026)
- 7.1.3 Global 5 Nucleotidase Revenue by Region (2027-2032)
- 7.1.4 Global 5 Nucleotidase Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America 5 Nucleotidase Revenue (2021-2032)
- 7.2.2 North America 5 Nucleotidase Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe 5 Nucleotidase Revenue (2021-2032)
- 7.3.2 Europe 5 Nucleotidase Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific 5 Nucleotidase Revenue (2021-2032)
- 7.4.2 Asia-Pacific 5 Nucleotidase Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa 5 Nucleotidase Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa 5 Nucleotidase Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Bristol-Myers Squibb Co
- 8.1.1 Bristol-Myers Squibb Co Company Information
- 8.1.2 Bristol-Myers Squibb Co Business Overview
- 8.1.3 Bristol-Myers Squibb Co 5 Nucleotidase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Bristol-Myers Squibb Co 5 Nucleotidase Product Portfolio
- 8.1.5 Bristol-Myers Squibb Co Recent Developments
- 8.2 Corvus Pharmaceuticals Inc
- 8.2.1 Corvus Pharmaceuticals Inc Company Information
- 8.2.2 Corvus Pharmaceuticals Inc Business Overview
- 8.2.3 Corvus Pharmaceuticals Inc 5 Nucleotidase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Corvus Pharmaceuticals Inc 5 Nucleotidase Product Portfolio
- 8.2.5 Corvus Pharmaceuticals Inc Recent Developments
- 8.3 Innate Pharma SA
- 8.3.1 Innate Pharma SA Company Information
- 8.3.2 Innate Pharma SA Business Overview
- 8.3.3 Innate Pharma SA 5 Nucleotidase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Innate Pharma SA 5 Nucleotidase Product Portfolio
- 8.3.5 Innate Pharma SA Recent Developments
- 8.4 MedImmune LLC
- 8.4.1 MedImmune LLC Company Information
- 8.4.2 MedImmune LLC Business Overview
- 8.4.3 MedImmune LLC 5 Nucleotidase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 MedImmune LLC 5 Nucleotidase Product Portfolio
- 8.4.5 MedImmune LLC Recent Developments
- 8.5 Surface Oncology Inc
- 8.5.1 Surface Oncology Inc Company Information
- 8.5.2 Surface Oncology Inc Business Overview
- 8.5.3 Surface Oncology Inc 5 Nucleotidase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Surface Oncology Inc 5 Nucleotidase Product Portfolio
- 8.5.5 Surface Oncology Inc Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 5 Nucleotidase Value Chain Analysis
- 9.1.1 5 Nucleotidase Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 5 Nucleotidase Production Mode & Process
- 9.2 5 Nucleotidase Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 5 Nucleotidase Distributors
- 9.2.3 5 Nucleotidase Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst